



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 19, 2020

Frank Ruffo  
Chief Financial Officer  
Aclaris Therapeutics, Inc.  
640 Lee Road, Suite 200  
Wayne, PA 19087

**Re: Aclaris Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed March 13, 2020**  
**File No. 333-237163**

Dear Mr. Ruffo:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Mark Ballantyne